COFOE MEDICAL (Cofoe Medical Technology Co., Ltd.) disclosed that its board approved a 2026 interim profit distribution plan on 28 August 2026, proposing a cash dividend of RMB6 (tax inclusive) for every 10 shares held. The proposal will be submitted to the company’s third extraordinary general meeting for final approval. No bonus shares or capital-reserve conversion is included in the plan.

Based on 227.13 million shares eligible for distribution—after excluding 8.77 million treasury shares held for repurchase—the preliminary dividend outlay is estimated at RMB136.28 million. Should the share count change before the record date, the per-share payout ratio will remain unchanged and the total cash amount will be adjusted accordingly.

Interim unaudited results show net profit attributable to shareholders of RMB202.26 million for the first half of 2026. Parent-company net profit stood at RMB97.17 million. Undistributed profit totaled RMB716.27 million on a consolidated basis and RMB230.61 million at the parent level; dividend capacity is capped at the lower parent-company figure. Statutory surplus reserve requirements have been met.

The cash dividend will be paid in Renminbi for A-shares and in Hong Kong dollars for H-shares, using the average RMB/HKD central parity rate quoted by the People’s Bank of China over the five business days preceding shareholder approval.

The board stated that the proposed payout balances profitability, financial strength, and future development needs, and will not strain the company’s liquidity.